2,4-dioxo-3-quinazolinylaryl sulfonylureas

Details 2,4-dioxo-3-quinazolinylaryl sulfonylureas 2,4-dioxo-3-quinazolinylaryl sulfonylureas

2006-09-19

2006-09-19

McKenzie, Thomas C. (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C514S266240

Reexamination Certificate

active

07109332

ABSTRACT:
2,4-Dioxo-3-quinazolinylaryl sulfonylurea compounds having the formula:whereinR is a member selected from the group consisting of H and C1-6alkyl;R1is a member selected from the group consisting of H, C1-6alkyl, C1-6haloalkyl, C3-5cycloalkyl and C3-5cycloalkyl-alkyl;R2is a member selected from the group consisting of H, halogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C1-6alkoxy, cyano and —C(O)R2a, wherein R2ais a member selected from the group consisting of C1-6alkoxy and (C1-6alkyl)0-2amino;L is a1to3carbon linking group selected from the group consisting of —CH2—, —CH(CH3)—, —CH2CH2—, —CH2CH(CH3)— and —CH2CH2CH2—;L1is a linking group selected from the group consisting of a bond and —CH2—;L2is a linking group selected from the group consisting of a bond, —NH— and —CH2—; andAr1is an aromatic ring selected from the group consisting of benzene, pyridine and pyrimidine;are provided. The compounds are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.

REFERENCES:
patent: 2002/0077486 (2002-06-01), Scarborough et al.
patent: WO 99/05144 (1999-02-01), None
patent: WO 99/36425 (1999-07-01), None
patent: WO 01/57037 (2001-08-01), None
Berge, S.M., et al, “Pharmaceutical salts.”J. Pharmaceut. Sci., vol. 66, No. 1., pp. 1-19 (1977).
Fratantoni J.C. and B.J. Poindexter, “Measuring platelet aggregation with microplate reader. A new technical approach to platelet aggregation studies.”Am. J. Clin. Pathol., vol. 94, No. 5; pp. 613-617 (1990).
Fredholm, B.B. et al., “Towards a revised nomenclature for P1 and P2 receptors.”Trends Pharmacol. Sci., vol. 18, No. 3; pp. 79-82 (1997).
Hechler, B. et al., “The P2Y1 receptor is necessary for adenosine 5′-diphosphate-Induced platelet aggregation.”Blood, vol. 92, No. 1; pp. 152-159 (1998).
Hollopeter, G. et. al., “Identification of the platelet ADP receptor targeted by antithrombotic drugs.”Nature, vol. 409, No. 6817; pp. 202-207 (2001).
Humphries et al., “A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis.”Trends Pharmacol. Sci., vol. 16, No. 6; pp. 179-181 (1995).
Ingall, A.H. et al., “Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy.”J. Med. Chem., vol. 42, No. 2, pp. 213-220 (1999).
Jantzen, H.M. et al., “Evidence for two distince G-protein-coupled ADP receptors mediating platelet activation.”Thromb. Haemost., vol. 81, No. 1; pp. 111-117 (1999).
King, B.F. et al., “Metabotropic receptors for ATP and UTP: exploring the correspondence between native and recombinant nucleotide receptors.”Trends Pharmacol. Sci.vol. 19, No. 12; pp. 506-514 (1998).
Kunapuli, S.P. and J.L. Daniel, “P2 receptor subtypes in the cardiovascular system.”Biochem. J., vol. 336, No. 3; pp. 513-523 (1998).
Kunapuli, S.P., “Multiple P2 receptor subtypes on platelets: a new interpretation of their function.”Trends Pharmacol. Sci., vol. 19, No. 10; pp. 391-394 (1998).
Mills, D.C.B. “ADP receptors on platelets.”Thromb. Haemost., vol. 76, No. 6, pp. 835-856 (1996).
Quinn, M.J. and D.J. Fitzgerald, “Ticlopidine and clopidogrel.”Circulation, vol. 100, No. 15; pp. 1667-1672 (1999).
Urban, F.J. et al., “Novel synthesis of 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]urea, an anti-inflammatory agent.”Synth. Comm., vol. 33, No. 12, pp. 2029-2043 (2003).

Affiliated with

Also associated with

Rating

2,4-dioxo-3-quinazolinylaryl sulfonylureas does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2,4-dioxo-3-quinazolinylaryl sulfonylureas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,4-dioxo-3-quinazolinylaryl sulfonylureas will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3563379